Free Trial

TransMedics Group (TMDX) Stock Forecast & Price Target

TransMedics Group logo
$92.01 +1.07 (+1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$90.32 -1.70 (-1.84%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TransMedics Group - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
7
Buy
5

Based on 12 Wall Street analysts who have issued ratings for TransMedics Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 7 have given a hold rating, and 5 have given a buy rating for TMDX.

Consensus Price Target

$113.30
23.14% Upside
According to the 12 analysts' twelve-month price targets for TransMedics Group, the average price target is $113.30. The highest price target for TMDX is $175.00, while the lowest price target for TMDX is $80.00. The average price target represents a forecasted upside of 23.14% from the current price of $92.01.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TMDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for TransMedics Group and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TMDX Analyst Ratings Over Time

TypeCurrent Forecast
11/11/25 to 11/11/26
1 Month Ago
10/12/25 to 10/12/26
3 Months Ago
8/13/25 to 8/13/26
1 Year Ago
11/11/24 to 11/11/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
Hold
7 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$113.30$121.00$124.18$130.73
Forecasted Upside23.14% Upside54.79% Upside38.53% Upside7.03% Upside
Consensus RatingHoldHoldHoldModerate Buy

TMDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TMDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

TransMedics Group Stock vs. The Competition

TypeTransMedics GroupHealthcare CompaniesBroader Market
Consensus Rating Score
2.42
2.32
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside23.14% Upside110.66% Upside13.64% Upside
News Sentiment Rating
Positive News

See Recent TMDX News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/9/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Patrick Wood
Not Rated
Boost TargetNeutral$77.00 ➝ $88.00-6.19%
11/6/2026
Jason Mills
Not Rated
Boost TargetBuy$95.00 ➝ $120.00+73.96%
11/6/2026
Allen Gong
Allen Gong
4 of 5 stars
Boost TargetNeutral$73.00 ➝ $85.00-3.67%
11/6/2026Boost TargetBuy$106.00 ➝ $110.00+25.89%
11/2/2026 UpgradeStrong Sell ➝ Hold
10/7/2026Initiated CoverageOverweight$120.00+49.48%
9/8/2026Reiterated RatingBuy$120.00+37.73%
8/31/2026 UpgradeHold (C-) ➝ Hold (C)
8/5/2026Reiterated RatingOverweight$120.00 ➝ $100.00+35.96%
6/18/2026Boost TargetHold$75.00 ➝ $80.00+9.26%
The Withdrawal You'll Never See on Your Statement (Ad)

A proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.tc pixel

Download the free 2026 Gold IRA Guide to protect your retirement savings.
5/6/2026 DowngradeOutperform ➝ Market Perform
12/2/2025Boost TargetEqual Weight$123.00 ➝ $135.00-7.50%
10/13/2025Initiated CoverageBuy$145.00+35.15%
9/16/2025Initiated CoverageOutperform$155.00+35.62%
12/11/2024 Lower TargetOutperform$150.00 ➝ $120.00+73.94%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:36 PM ET.


TMDX Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for TransMedics Group is $113.30, with a high forecast of $175.00 and a low forecast of $80.00.

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TMDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMDX, but not buy additional shares or sell existing shares.

According to analysts, TransMedics Group's stock has a predicted upside of 23.14% based on their 12-month stock forecasts.

Over the previous 90 days, TransMedics Group's stock had 2 upgrades by analysts.

TransMedics Group has been rated by research analysts at Barclays, Canaccord Genuity Group, JPMorgan Chase & Co., Needham & Company LLC, TD Cowen, UBS Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like TransMedics Group more than other "healthcare" companies. The consensus rating score for TransMedics Group is 2.42 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how TMDX compares to other companies.


MarketBeat monitors more than a dozen sources for TransMedics Group analyst ratings, with the most recent rating issued on 11/9/2026.
From Our Partners